预约演示
更新于：2025-10-23
Interferon beta 1a(The University of Southampton)
干扰素β-1a(The University of Southampton)
更新于：2025-10-23
概要
基本信息
非在研机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 12364
当前序列信息引自: *****
关联
10
项与 干扰素β-1a(The University of Southampton) 相关的临床试验NCT06999603
A Phase 2, Two-part Study to Assess the Safety, Antiviral Biomarker Responses, and Efficacy of Inhaled SNG001 for the Treatment of Patients With a Confirmed Respiratory Virus Infection Undergoing Invasive Mechanical Ventilation
The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied.
The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo.
In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital.
In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.
The study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo.
In Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital.
In Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.
开始日期2025-07-01 |
申办/合作机构 |
ISRCTN30482473
A Phase II, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation
开始日期2025-03-31 |
申办/合作机构- |
IRCT20200721048159N4
Comparison of Effectiveness of Remdesivir with Remdesivir and Interferon Beta-1 a Treatment Regime on Clinical Outcome of Covid 19 Patients
开始日期2021-07-23 |
申办/合作机构- |
100 项与 干扰素β-1a(The University of Southampton) 相关的临床结果
登录后查看更多信息
100 项与 干扰素β-1a(The University of Southampton) 相关的转化医学
登录后查看更多信息
100 项与 干扰素β-1a(The University of Southampton) 相关的专利（医药）
登录后查看更多信息
76
项与 干扰素β-1a(The University of Southampton) 相关的文献（医药）2025-07-01·ARQUIVOS DE NEURO-PSIQUIATRIA
Active tuberculosis and multiple sclerosis: the importance of screening before treatment
Article
作者: Oliveira, Enedina Maria Lobato de ; Amorim, Leizian de Souza ; Zaidan, Paloma Peter Travassos ; Menezes, Felipe Toscano Lins de
Abstract:
Tuberculosis (TB), a chronic infection caused by the Mycobacterium tuberculosis complex, has an increased risk of reactivation in conditions that affect the immune system, such as MS, and its treatment with disease-modifying drugs (DMDs). The present is a retrospective study of 2,036 patients diagnosed with MS followed at the Department of Neurology and Neurosurgery of Escola Paulista de Medicina, Universidade Federal de São Paulo, from February 1994 to September 2023. Of that total, 6 were included in this case series, taking different DMDs: fingolimod (n = 2), interferon beta 1a (n = 2), glatiramer acetate (n = 1) and cyclophosphamide (n = 1). In our study, two patients experienced worsening disability during tuberculosis treatment, while three others had increased disability after completing treatment. We reinforce the importance of screening all patients eligible for DMD treatment, especially the highly effective modern ones, and the importance of developing research-based guidelines for screening infectious diseases among patients with MS.
2025-02-01·CLINICAL PHARMACOLOGY & THERAPEUTICS
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
Article
作者: Hutton, George J. ; Aparasu, Rajender R. ; Lin, Ying ; Varisco, Tyler J. ; Essien, Ekere J. ; Li, Jieni
In patients with multiple sclerosis (MS), infections represent a significant concern, particularly given the immunomodulatory effects of disease‐modifying agents (DMAs). High‐efficacy DMAs (heDMAs) play a pivotal role in delaying MS progression, yet their use also raises concerns regarding the risk of infection. This study aimed to compare the infection risk with the use of heDMA and moderate‐efficacy disease‐modifying agents (meDMAs) in MS patients. This retrospective cohort study involved adult (18–64 years) MS patients with incident DMA use based on the 2015–2019 MarketScan Commercial Claims and Encounters Database. Patients initiating heDMAs (natalizumab, alemtuzumab, and ocrelizumab) or meDMAs (interferon beta‐1a, interferon beta‐1b, fingolimod, teriflunomide, dimethyl fumarate, and glatiramer acetate) were included. The outcomes of interest were comparative risk of overall infection, serious infection, and frequently reported types of infection. Adjusted hazard ratios (aHR) were estimated in inverse probability treatment weighting (IPTW) based on Cox proportional hazard models. Among 10,003 eligible incident DMA users, 22.92% of patients initiated heDMAs. The IPTW‐CPH model revealed that patients with heDMAs were associated with a higher risk of serious infection (aHR: 1.24, 95% confidence interval (CI): 1.06–1.44) and urinary tract infection (UTI; aHR: 1.21, 95% CI: 1.14–1.30). Sensitivity analyses with different follow‐up periods yielded consistent findings with the main analyses. In MS, heDMAs were associated with a greater risk of serious infection and UTI compared with meDMAs. These findings suggest the need to carefully monitor and manage the infection risk to optimize the use of heDMAs in MS.
2024-05-01·Journal of neurology
Correction to: The impact of metformin use on the outcomes of relapse‑remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open‑label randomized controlled trial
作者: Abdelgaied, Mohamed Y ; Solayman, Mohamed H ; Rashad, Mohamed Hamed ; El-Tayebi, Hend M
Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disorder.Elevated levels of pro-inflammatory mediators and some oxidative stress parameters can accelerate the demyelination process.We aimed to investigate the efficacy and safety of metformin as an adjuvant therapy to interferon beta 1a (IFNβ-1a) in relapsing-remitting multiple sclerosis (RRMS) patients.Eighty RRMS patients were equally divided into 2 groups: the intervention group receiving IFNβ-1a plus 2 gm of metformin once daily and the control group receiving IFNβ-1a alone.Interleukin 17 (IL17), interleukin 22 (IL22), malondialdehyde (MDA), T2 lesions in magnetic resonance imaging (MRI) and expanded disability status scale (EDSS) were assessed at the baseline and then after 6 mo.At baseline, there were no statistically significant differences between the two groups (p > 0.05).After 6 mo, the change in the median (interquartile range) of the results for both the intervention and control group were; IL17 (- 1.39 (4.19) vs - 0.93 (5.48), p = 0.48), IL22 (- 0.14 (0.48) vs - 0.09 (0.6), p = 0.53), and EDSS (0 vs 0, p = 1), resp.The mean (standard deviation) change in MDA for the intervention and control group was - 0.93 (2.2) vs - 0.5 (2.53), p = 0.038, resp.For MRI results, 21 patients had stationary and regressive course and 1 patient had a progressive course in the intervention arm vs 12 patients had stationary and regressive course and 4 had a progressive course in the control arm, p = 0.14.Adding metformin to IFNβ-1a demonstrated a potential effect on an oxidative stress marker (MDA).However, there is no statistically significant effect on immunol., MRI and clin. outcomes.We recommend larger scale studies to confirm or negate these findings.
25
项与 干扰素β-1a(The University of Southampton) 相关的新闻（医药）2025-03-25
导语：在成立 50 周年前夕，全球生物医药巨头百健（Biogen）宣布将斥资打造全新全球总部，选址剑桥 Kendall Common 创新园区。这一决策不仅标志着其回归生物技术发源地的战略决心，更折射出药企在研发效率与成本压力下的破局尝试。随着多发性硬化症（MS）药物收入下滑，百健正以 “空间革命” 重构未来竞争力。一、50 年沉浮：从剑桥到剑桥的 “轮回”
1978 年，百健诞生于剑桥 Kendall Square 的实验室中，凭借干扰素 β-1a（Avonex）等 MS 药物崛起为行业巨头。2010 年，公司曾短暂迁至韦斯顿（Weston），但 2013 年即回归剑桥，印证了其对这一生物技术圣地的依赖。此次签约的 75 Broadway 大楼，距其现总部仅 5 分钟步行距离，租期 15 年，总面积达 58 万平方英尺，预计 2028 年投入使用。
“剑桥塑造了百健的基因。”CEO 克里斯・维埃巴赫（Chris Viehbacher）在声明中强调，“新总部将成为连接科学突破与商业转化的神经中枢。”二、创新中心：实验室、协作空间与生态融合
新总部将整合研发、技术与商业团队，打造 “未来实验室” 与 “生物谷协作中心”（Biogen CoLab），后者将向学术机构、非营利组织开放，成为公众接触生命科学的窗口。建筑设计融入环保理念，采用低碳材料与智能能源系统，呼应百健 “净零排放” 目标。
值得关注的是，该项目由麻省理工学院（MIT）与黑石集团旗下 BioMed Realty 联合开发，依托 MIT 的科研资源与 Kendall Square 的产业集群效应。百健将作为唯一企业租户，独享定制化研发设施，加速神经科学、肿瘤等管线推进。三、战略深意：应对 MS 危机与行业变局
此次搬迁正值百健转型阵痛期：
MS 业务下滑：2024 年 MS 药物收入占比降至 58%，同比下降 9%，而竞争对手诺华的 Kisqali 与罗氏的 Ocrevus 正蚕食市场。
裁员与成本优化：2023 年启动裁员 11%（约 2000 人），2025 年初完成研发团队重组，将资源聚焦阿尔茨海默病（Aduhelm）、脊髓性肌萎缩症（SMA）等管线。
行业分析师指出，百健此举旨在通过物理空间整合提升跨部门协作效率，同时借助剑桥的人才库与初创企业生态，捕捉新机遇。“在管线竞争白热化的今天，地理位置的‘创新密度’已成为药企核心竞争力。” 投行 Jefferies 分析师评论道。四、行业镜像：药企总部的 “迁徙潮”
百健并非孤例，近年跨国药企正加速向生物技术中心集中：
辉瑞：2024 年宣布在剑桥投资 10 亿美元扩建研发中心。
诺华：将全球数字创新中心设在 Kendall Square。
阿斯利康：在波士顿地区布局肿瘤与基因治疗团队。
这种 “总部中心化” 趋势源于三大驱动因素：
人才争夺战：剑桥地区聚集哈佛、MIT 等顶尖高校，生物科技人才密度全美第一。
研发效率革命： proximity to CROs（如 Charles River）与初创企业可缩短药物开发周期。
政策与资本引力：马萨诸塞州通过税收优惠吸引药企投资，2024 年生物技术融资额占全美 18%。五、挑战与隐忧
尽管前景可期，百健的 “空间战略” 仍面临多重挑战：
成本压力：剑桥实验室租金较周边地区高 30%，长期租赁或拖累利润率。
文化整合风险：研发与商业团队的物理融合能否转化为创新协同？历史上药企内部部门壁垒常导致效率低下。
管线不确定性：Aduhelm 因争议性定价与疗效数据，2024 年销售额仅 3.2 亿美元，距预期相去甚远。六、未来展望：50 周年的 “重生之战”
2028 年，百健将以新总部为起点，开启 “第二个 50 年”。其战略路径已清晰：
押注神经科学：推进阿尔茨海默病、帕金森病等领域的基因疗法与单抗开发。
布局罕见病：通过 Spinraza（SMA）与反义寡核苷酸技术拓展高壁垒市场。
数字化转型：在新总部嵌入 AI 药物设计平台，加速靶点发现。
“这不仅是一次物理搬迁，更是一次组织变革。” 行业观察家指出，“百健需要证明，空间重构能转化为真正的创新动能。”
结语从基因街的实验室到全球总部，百健的 50 年轨迹映射着生物技术产业的兴衰变迁。当新总部在 2028 年拔地而起，它或将见证一家老牌药企的涅槃重生 —— 而这场 “空间革命” 的成败，也将为整个行业提供转型样本。参考来源：https://www.fiercepharma.com/pharma/biogen-plots-2028-headquarters-shift-new-innovation-hub-cambridge
识别微信二维码，添加生物制品圈小编，符合条件者即可加入
生物制品微信群！
请注明：姓名+研究方向！
版
权
声
明
本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。
基因疗法核酸药物
2023-07-15
DUBLIN, July 14, 2023 /PRNewswire/ -- The "Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2023" clinical trials has been added to
ResearchAndMarkets.com's offering.
With an extensive focus on 65+ companies and 70+ pipeline drugs, this report provides a detailed analysis of the current scenario and growth prospects across the indication.
The report encompasses a comprehensive overview of the pipeline drug profiles, covering both clinical and nonclinical stage products. Additionally, it includes a thorough assessment of therapeutics, considering product type, stage, route of administration, and molecule type. Inactive pipeline products in this space are also highlighted, providing a holistic view of the COPD pipeline landscape.
To provide a comprehensive understanding, this report outlines the present scenario and growth prospects in the COPD field. It offers detailed insights into the disease overview and treatment guidelines for Chronic Obstructive Pulmonary Disease, setting the stage for a deeper exploration of the pipeline landscape.
Furthermore, the report delves into the commercial assessment and clinical assessment of the pipeline products under development. It provides detailed descriptions of each drug, including their mechanisms of action, clinical studies, NDA approvals (if any), and comprehensive product development activities.
This encompasses technology, COPD collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant product-related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease Emerging Drugs Chapters
This segment of the Chronic Obstructive Pulmonary Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Obstructive Pulmonary Disease Emerging Drugs
Benralizumab: AstraZeneca
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin-5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction.
Dupilumab: Sanofi
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL) that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reactions, and rhinosinusitis.
Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is under investigation for its potential therapeutic use in chronic obstructive pulmonary disease and is currently in the Phase III stage of development.
Tezepelumab: Amgen
Tezepelumab (Tezspire) is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Specifically, TEZSPIRE targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway inflammation associated with severe asthma.
TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses, and other airborne particles. Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity. Blocking TSLP may prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of asthma exacerbations and improved asthma control.
Tezspire is being developed in collaboration with AstraZeneca and is currently being evaluated in Phase II to treat patients with chronic obstructive pulmonary disease.
SNG001: Synairgen
SNG001 boosts antiviral responses in the lungs, has a beneficial effect on lung function, and in more difficult to treat patients, improves asthma control during cold infections. The drug is currently being evaluated in the Phase II stage of development to treat patients with COPD.
GSK3923868: GlaxoSmithKline
GSK3923868, is a PI4kb inhibitor in development as a treatment for viral COPD exacerbations. It belongs to the class of antiasthmatics. The drug acts as a 1-phosphatidylinositol-4-kinase inhibitor. Currently, the drug is in Phase I of its clinical trial evaluation for the treatment of chronic obstructive pulmonary disease.
Chronic Obstructive Pulmonary Disease: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Obstructive Pulmonary Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic Obstructive Pulmonary Disease
There are approx. 65+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
Phases
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Product Type
Chronic Obstructive Pulmonary Disease Report Insights
Chronic Obstructive Pulmonary Disease Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Key Players
Sanofi
AstraZeneca
Amgen
Synairgen
GlaxoSmithKline
Eisai
Meridigen Biotech
Chiesi
EmeraMed Limited
Verona Pharma
Tetherex Pharmaceuticals
Mereo BioPharma
Key Products
Lemborexant
UMC119-06
CHF5259
Emeramide
Ensifentrine
SNG001
GSK3923868
Benralizumab
Dupilumab
Tezepelumab
SelK2
BCT197
For more information about this clinical trials report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
临床2期临床3期免疫疗法临床1期
2022-10-17
·药智网
曾经一度被寄予厚望的新冠特效药，在全球疫情逐渐消退的当下，却接连爆出“翻车”的消息。近日，默沙东发布了Molnupiravir两项真实世界临床证据和一项非临床研究进展结果。其中一项由牛津大学资助的开放、前瞻性真实世界PANORAMIC的研究数据初步分析结果显示，在英国进行的针对＜65岁接种疫苗的成年人中，就减少住院人数和死亡人数方面而言，Molnupiravir添加到常规护理与仅使用常规护理相比没有任何差异，到第28天的住院和死亡的发生率，两组均为0.8%。通俗地说，这药吃了个寂寞，和安慰剂没有任何差别。Molnupiravir是全球首款获得授权的口服抗新冠病毒药物，属于新型核糖核苷类似物前药，用于治疗经SARS-CoV-2检测呈阳性、确诊轻度至中度新冠病毒病（新冠肺炎）、且有潜在重症（包括住院或死亡）风险的成年患者。这款由默沙东研发上市的抗新冠药物，已经在全球超过40多个国家和地区上市，就在9月28日，默沙东与国药集团签署协议，将Molnupiravir在中国的经销权和独家进口权授予国药集团。全球另一款抗新冠病毒的明星药物，由辉瑞研发上市的Paxlovid，也发现了疗效欠佳的临床证据。今年8月，在《新英格兰医学杂志》上发表的一项研究显示，对于40-60岁的患者来说，在接受Paxlovid治疗与不接受Paxlovid治疗的患者中，住院率为每10万人15.2例VS每10万人15.8例，二者相差并不大。但是研究也显示，Paxlovid对老年人确实有一定效果。具体来说，在参与研究的4.3万名65岁以上的新冠患者中，接受Paxlovid治疗的患者住院率为每10万人14.7例，而在未经治疗的患者住院率每10万人58.9例。此外，对Paxlovid还有另外一个更严重的质疑，就是一些患者在停药后，新冠症状出现了反弹，比如包括美国总统拜登、辉瑞CEO艾伯乐在内，都曾在服药后发生了“复阳”症状。除了以上两款已上市的知名药物开始“爆雷”以外，几款正在研发中的抗新冠病毒药物也纷纷传出坏消息。10月15日，日本富士胶片公司正式对外宣布，已决定停止研发其新冠治疗药物Avigan(法匹拉韦)，原因是在对患者的临床试验中未能确认药物的有效性，以及重症率较低的Omicron毒株成为主流，令口服药的需求急剧减少。富士胶片从去年4月展开法匹拉韦的临床试验，原先目标是招募316名患者，但直至今年3月为止，只有84名患者进入临床试验，而且分析了受试者的数据后，显示法匹拉韦未能对预防重症产生有意义的效用。在今年更早的2月21日，美国Synairgen公司也宣布，SNG001治疗新冠肺炎住院患者的临床III期SPRINTER研究，未达到其主要或关键次要疗效终点，宣告研发失败。受此消息影响，Synairgen公司股价下跌84%。关于已获批药物上市后表现不佳，以及在研药物的失败，学术界有多种解释，主要的原因集中在新冠病毒株的变异；有专家指出，以病毒的某个单分子为靶点的小分子口服药对付不断变异的病毒，出现力不从心、效力欠佳的情况可以说是必然的。如果抗新冠病毒小分子药物的时效性如此之短，甚至在药物上市的时刻，就是治疗效力开始大幅衰减的时刻，那么抗新冠病毒小分子药物的临床意义，可能要大打折扣。目前全球已有4款新冠口服药上市，其中真实生物的阿兹夫定和辉瑞的Paxlovid两款药物，已经在中国获批上市。此外还有礼来和Incyte的巴瑞替尼老药新用，用于需要补充氧的新冠患者，于2021年4月在日本上市，在美国获批EUA；默沙东的莫奈拉韦最早于2021年11月在英国获批上市，随后在日本上市、在美国获批EUA，目前已向中国提交NDA。再看中国市场，目前虽然只有真实生物的阿兹夫定一款国产药物获批，但是国内还有一支浩浩荡荡的新冠特效药研发大军，包括：君实生物、云顶新耀、先声药业、歌礼制药、科兴制药、开拓药业、盟科药业、众生睿创、盘龙药业、广生中霖、广生堂，等等。希望他们可以创造奇迹。来源 | 医药投资部落（药智网获取授权转载）撰稿 | 医药投资部落责任编辑 | 八角声明：本文系药智网转载内容，图片、文字版权归原作者所有，转载目的在于传递更多信息，并不代表本平台观点。如涉及作品内容、版权和其它问题，请在本平台留言，我们将在第一时间删除。— Tips —如果您有医药行业相关的线索或对医药政策、研发创新、资本市场、产业发展有深度观察欢迎投稿给我们马老师 18323856316（同微信）邮箱：maxuelian@yaozh.com发现“分享”和“赞”了吗，戳我看看吧
小分子药物疫苗生物类似药
100 项与 干扰素β-1a(The University of Southampton) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 干扰素β-1a(The University of Southampton) |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 阿根廷 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 比利时 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 巴西 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 哥伦比亚 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 法国 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 德国 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 印度 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 以色列 | 2021-01-12 | |
| 新型冠状病毒感染 | 临床3期 | 意大利 | 2021-01-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | - | 憲遞糧鹹餘範鹽觸鬱鬱(艱獵鏇餘餘襯鹹製製鑰) = 襯製醖壓廠網選範鏇廠 獵齋壓窪齋淵膚衊築鏇 (網憲衊襯繭積廠願襯繭 ) | 积极 | 2023-11-01 | |||
Blinded pooled placebo | 憲遞糧鹹餘範鹽觸鬱鬱(艱獵鏇餘餘襯鹹製製鑰) = 選憲範夢鹽齋憲膚襯淵 獵齋壓窪齋淵膚衊築鏇 (網憲衊襯繭積廠願襯繭 ) | ||||||
临床3期 | 623 | (SNG001) | 糧願構繭膚鏇鏇餘顧齋(窪觸壓顧淵鹹鑰鹽獵顧) = 憲願憲襯衊蓋醖遞顧積 鹹醖醖顧顧艱鏇鏇糧顧 (顧鏇壓膚憲獵築鹽願構, 憲鏇淵構衊願觸選鬱齋 ~ 糧願窪願鹹積繭構糧襯) 更多 | - | 2023-03-27 | ||
Placebo (Placebo) | 糧願構繭膚鏇鏇餘顧齋(窪觸壓顧淵鹹鑰鹽獵顧) = 廠繭範觸憲觸糧網顧繭 鹹醖醖顧顧艱鏇鏇糧顧 (顧鏇壓膚憲獵築鹽願構, 選壓憲繭鏇範製繭網築 ~ 蓋簾鏇窪鑰觸糧鏇積繭) 更多 | ||||||
临床2期 | 220 | 襯艱糧鑰顧獵繭獵廠淵(膚膚餘觸窪憲廠鬱鹹簾) = 網淵願積網夢簾構淵繭 糧窪窪繭醖繭範積鹹築 (鏇壓鹹築壓鹽構蓋衊觸 ) 更多 | 积极 | 2022-10-04 | |||
Placebo | 襯艱糧鑰顧獵繭獵廠淵(膚膚餘觸窪憲廠鬱鹹簾) = 願積餘醖淵鬱艱夢糧鑰 糧窪窪繭醖繭範積鹹築 (鏇壓鹹築壓鹽構蓋衊觸 ) 更多 | ||||||
临床3期 | 623 | 艱範膚鬱願齋憲鏇憲積(糧淵範膚積憲繭願願鏇) = 廠壓糧願範簾淵鏇壓簾 遞廠簾淵獵顧鹽積積淵 (齋鹽膚壓鹹鏇憲築鬱積 ) | - | 2022-05-15 | |||
临床3期 | 623 | Standard of Care+SNG-001 | 網鑰鑰繭鑰顧餘憲願夢(壓襯襯窪壓憲糧淵夢壓) = 衊鏇襯顧憲鹽築艱網築 繭積範觸淵選齋築構襯 (醖餘選夢餘鑰齋鏇觸簾, 7 ~ 9) 更多 | 不佳 | 2022-02-22 | ||
Standard of Care+Placebo | 網鑰鑰繭鑰顧餘憲願夢(壓襯襯窪壓憲糧淵夢壓) = 膚憲積製範鏇鏇鹹鹹簾 繭積範觸淵選齋築構襯 (醖餘選夢餘鑰齋鏇觸簾, 7 ~ 8) 更多 | ||||||
临床2期 | 101 | 築簾鬱窪夢網觸餘鬱淵(餘鹽艱製廠鬱製糧艱構) = 糧夢淵衊鏇築築齋醖鹽 襯醖齋齋襯顧壓艱餘鹹 (鏇繭壓範鬱築糧蓋餘淵 ) 更多 | 积极 | 2021-02-01 | |||
Placebo | 築簾鬱窪夢網觸餘鬱淵(餘鹽艱製廠鬱製糧艱構) = 築觸壓願範鏇鏇醖鹽構 襯醖齋齋襯顧壓艱餘鹹 (鏇繭壓範鬱築糧蓋餘淵 ) 更多 | ||||||
临床2期 | 121 | (AZD9412) | 衊構醖襯遞願選構築遞 = 顧窪鏇齋簾簾窪顧壓壓 製壓選壓簾繭繭鹹遞繭 (壓艱齋鏇艱艱艱簾願繭, 廠膚鹽餘襯鏇鏇築顧繭 ~ 觸觸糧憲範鹹艱簾鹽簾) 更多 | - | 2019-01-15 | ||
placebo (Placebo) | 衊構醖襯遞願選構築遞 = 鏇築廠觸廠憲觸淵襯觸 製壓選壓簾繭繭鹹遞繭 (壓艱齋鏇艱艱艱簾願繭, 遞艱鬱壓艱衊齋艱齋獵 ~ 膚鬱選顧鏇願鏇鹽糧觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用